Karyopharm Therapeutics | KPTI - Capital Y Las Reservas





Capital Y Las Reservas Cambio Fecha
AbbVie USD -5.94B 721M 2026-06
Abbott USD 52.06B 69M 2026-03
Amgen USD 11.69B 2.5B 2026-06
AstraZeneca USD 50.3B 2.96B 2026-06
BioCryst Pharmaceuticals USD -454.29M 99.55M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Eli Lilly USD 33.88B 2.68B 2026-06
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
GlaxoSmithKline GBP 17.64B 223M 2026-06
Incyte USD 6.34B 721.58M 2026-06
J&J USD 84.97B 3.78B 2026-06
Karyopharm Therapeutics USD -265.65M 27.28M 2026-03
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 41.93B 3.94B 2026-06
Nektar Therapeutics USD 576.22M 486.38M 2026-03
Novartis USD 41.95B 3.02B 2026-06
Novartis USD 38.93B 7.2B 2026-03
Pfizer USD 85.19B 4.91B 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 32.69B 1.11B 2026-06
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Takeda JPY 7.56T 215.7B 2026-06
Tectonic Therapeutic USD 230.42M 20.91M 2026-03
TG Therapeutics USD 604.08M 20.95M 2026-06
Ultragenyx Pharmaceutical USD -291M 55M 2026-06
Xencor USD 503.23M 12.4M 2026-06